Bratha

Part 4.3 — The Bodybuilding Realm

16 min read

This is Part 4.3 of 5 in the Performance Enhancement Series — the "Tier 3" continuation of the Fitness Series' Pharmacology chapter. The full path:

Table of Contents

Framing

This article covers the performance and aesthetic compounds — fat-burners, thyroid, pumps, and stage tools — that sit beside the anabolics. It is harm-reduction education, not medical advice or a protocol. Several of these (clenbuterol, T3, contest diuretics, insulin-adjacent agents) are genuinely dangerous and a few have killed people; doses are given only where they’re standard harm-reduction reference, and never for contest diuretics. The compounds are prescription-only, research chemicals, or banned substances in most jurisdictions, including Malaysia. Work with a physician.

The goal shifts: from protection to the look

The rest of Part 4 was about defense — keeping your heart, liver, and hormones intact. This sub-article is the opposite: the compounds whose entire job is performance and appearance — getting leaner, fuller, drier, more vascular, more conditioned. They’re neither anabolics (Part 3) nor protective ancillaries (Part 4.2); they’re the third drawer of the toolbox.

Two honest framings before the list:

  • This is the shiniest of the shiny objects. In 10 terms, the anabolics are already the margin; this drawer is the margin on the margin — overwhelmingly cut-phase and contest tools layered on a physique that’s already built. Most of the year, most people don’t need any of it.
  • Most of these you’ve already met. The Fit series’ Pharmacology chapter introduced clenbuterol, cardarine, and MK-677 as “Half-Natty” compounds. Here we look at them through the enhanced athlete’s lens — and through the framing that makes this drawer make sense: direct vs. indirect effects.

How to read a compound: direct vs. indirect

Every compound here has a direct mechanism (what it does at the receptor) and a set of prominent indirect effects (the downstream consequences that are usually the real reason people run it). Reading a compound by its indirect effects is how you actually predict what it'll do to your physique and performance. Each entry below is structured: direct mechanism → direct effect → the prominent indirect effects.

Fat loss & conditioning

Clenbuterol

  • Direct: a β2-adrenergic agonist (an asthma drug) that spikes the central nervous system and metabolic rate.
  • Direct effect: thermogenesis and direct lipolysis (fat-cell breakdown), raising basal metabolic rate.
  • Indirect effects: mild anti-catabolic muscle sparing in a steep deficit; bronchodilation → better oxygenation and aerobic output; sharper vascularity as fat strips and BP rises.
  • Caveats: real cardiovascular load — tachycardia, raised BP, and at higher doses/longer durations the wrong kind of cardiac hypertrophy (fibrotic). Used low-dose, short cycles, late in a cut, with taurine and potassium support and ketotifen to re-sensitise β2 receptors. (More in the Fit series.)

Ephedrine (and the ECA stack)

  • Direct: a sympathomimetic that raises catecholamine activity.
  • Direct effect: thermogenesis and appetite suppression.
  • Indirect effects: reduced lethargy and restored workout capacity at very low body fat (sub-6%), where energy craters. Classically stacked as ECA (ephedrine + caffeine + aspirin) for synergy.
  • Caveats: cardiovascular — BP and heart rate; not for anyone with hypertension or cardiac concerns.

Cardarine (GW-501516)

  • Direct: a PPAR-δ agonist — not a hormone or stimulant.
  • Direct effect: shifts the body’s primary fuel from glucose to fatty acids.
  • Indirect effects: ==its famous one is endurance — you stop “gassing out,”== because burning fat first spares muscle glycogen (so muscles stay full even when calories are low), and it improves the lipid panel (raises HDL, drops triglycerides). That lipid effect is why it doubles as a “super ancillary”.
  • Caveat: rodent studies at very high doses showed cancer — not a casual compound.

Yohimbine / Rauwolscine

  • Direct: an α2-adrenergic antagonist.
  • Direct/indirect effect: blocks the α2 “brake” on lipolysis in stubborn fat depots (lower back, abs), so it spot-mobilises that fat — but only in a fasted state (insulin neutralises it). The same mechanism covered in the Fit series’ Tier-1 fat-loss section.
  • Caveat: raises BP/heart rate and anxiety; fasted morning cardio use only.

Cytolin (a UGL blend)

  • What it is: in regional underground labs, “Cytolin” is typically a brand blend of clenbuterol with T3/T4 to maximise thyroid-driven thermogenesis.
  • Indirect effects: aggressive energy expenditure and fat loss — but it burns through glycogen fast, so expect muscle flatness unless carbs are carefully timed.
  • Caveat: it's a UGL blend — you're trusting a lab's ratio of two already-harsh compounds. Knowing exactly what (and how much) you’re taking is the whole Part 1 quality problem; running the components separately and dialled is the safer route.

Thyroid for cutting: T3 (vs. the protective T4)

Part 4.2 covered T4 (levothyroxine) in its protective role — replacing the thyroid output that GH burns through. T3 (liothyronine) is the aggressive version used here for fat loss:

  • Direct: the active thyroid hormone, raising metabolic rate directly (no conversion step).
  • Indirect effects: accelerated fat loss in a cut, overriding the metabolic slowdown of prolonged dieting — often paired with clenbuterol.
  • Caveats: it's catabolic to muscle and taxing on the heart. Demands FT3/FT4 tracking, conservative dosing (a ~25 mcg replacement-level dose is a different animal from hypermetabolic contest dosing), and a careful taper — abrupt cessation leaves the thyroid axis sluggish. A contest-prep tool, not a year-round one.

Metabolic & mitochondrial adjusters

The fat-burners above (clenbuterol, ephedrine) work by flogging the central nervous system. This newer drawer works underneath the CNS — at the mitochondria and the cell’s glucose machinery — to change how fuel is handled rather than just how fast it’s burned. The appeal is a far lower cardiovascular cost, which is why these are the backbone of a mini-cut aimed at restoring insulin sensitivity without crashing training.1

SLU-PP-332

  • Direct: an ERR (estrogen-related receptor) agonist.
  • Direct effect: mimics the cellular signalling of endurance exercise — “exercise in a molecule.”
  • Indirect effects: raised fat oxidation and metabolic rate without a stimulant load, so you get a fat-loss tailwind that doesn’t spike heart rate or BP the way clenbuterol does.
  • Caveat: a research chemical with scant human data — promising mechanism, thin evidence.

MOTS-c

  • Direct: a mitochondrial-derived peptide.
  • Direct/indirect effect: drastically enhances metabolic flexibility (the cell’s ability to switch cleanly between burning fat and glucose) and helps prevent diet-induced insulin resistance — the exact failure mode a long deficit creates. Pairs naturally with SLU-PP-332.
  • Caveat: peptide, research-tier; injectable, limited long-term data.

Methylene Blue

  • Direct: acts as an electron cycler in the mitochondrial electron transport chain.
  • Indirect effects: increases ATP production and helps clear metabolic waste during periods of intense oxidative stress — i.e., a hard cut.
  • Caveats: it's hormetic (a low dose helps, a high dose harms) and it's an MAOI — combining it with serotonergic drugs risks serotonin syndrome. Not a casual add; it also turns urine blue-green.

Glucose management for the cut (the "+" combo)

The fastest way to restore insulin-receptor sensitivity in a mini-cut is to clear glucose from three directions at once: ==Metformin + an SGLT2 inhibitor (empagliflozin / ertugliflozin) + Retatrutide.==2 The SGLT2 inhibitor forces the kidneys to dump excess glucose into the urine; metformin improves peripheral insulin sensitivity in muscle and lowers hepatic (liver) glucose output; retatrutide (a GLP-1/GIP/glucagon triple agonist) suppresses appetite and elevates metabolic rate. Several of these double as the year-round glucose ancillaries — which is why they’re tagged ”+”: they may already be running. (Retatrutide’s appetite crush makes it a cut tool, not a bulk one; full selection logic in Part 4.2.)

Fullness & recovery: MK-677

  • Direct: an oral ghrelin-receptor agonist that mimics hunger to force pulses of Growth Hormone (and downstream IGF-1).
  • Direct effect: elevated systemic GH/IGF-1 (Pathways 7 & 8).
  • Indirect effects: the headline is muscle fullness and vascularity — intracellular water and glycogen pushed inside the muscle belly, making you look fuller and tighter with veins closer to the skin; plus deep-sleep enhancement → recovery; plus (the strength angle) the intracellular hyper-hydration acts as a joint/tendon cushion that lets you handle heavier loads with less pain.
  • The pitfall: massive appetite stimulation — a feature on a bulk, a saboteur on a cut — and water retention that can blur conditioning and nudge glucose up.

Pumps & vascularity: tadalafil

You met tadalafil as a BP “super ancillary.” Here’s its aesthetic/performance face:

  • Direct: a PDE5 inhibitor — blocks the breakdown of cGMP → systemic vasodilation.
  • Indirect effects: unreal pumps (more blood volume forced into working muscle → a rigid structural framework that improves force transfer), persistent vascularity (wider, closer-to-surface veins even at rest), and faster ATP/nutrient delivery + lactic-acid clearance between sets — so peak strength holds into your 4th and 5th sets instead of dropping off.
  • Why it’s a favourite: it’s one of the rare compounds that pays off for both health (BP, endothelium) and aesthetics (pumps, vascularity) — genuinely dual-use.

Stage aesthetics: tanning and the diuretic line

Melanotan-2

  • Direct: a melanocortin agonist.
  • Indirect effects: skin pigmentation (a deep tan with less sun — useful for stage or photos), plus appetite reduction and improved erection quality.
  • Caveats: nausea and a darkening of moles/freckles; the long-term melanoma question means it’s not casual.

Contest diuretics: the line where this gets people killed

Pulling water for the stage with aggressive (often loop) diuretics is the single most dangerous thing in this entire series — it has killed competitors outright via potassium/electrolyte crashes and cardiac arrhythmia. There are no reference doses here, on purpose. This is expert-supervised, contest-week-only territory, and it is categorically different from the gentle, BP-driven [[Part 4.2 - Choosing Your Ancillaries|indapamide restraint]] in Part 4.2. If you are not a competitor with a coach and medical supervision, this does not belong anywhere near you.

Direct vs. indirect effects — the master table

CompoundDirect mechanismDirect effectProminent indirect effects
Clenbuterolβ2 agonistThermogenesis, lipolysisMuscle sparing; oxygenation/endurance; vascularity
Ephedrine (ECA)SympathomimeticThermogenesis, appetite ↓Energy/work capacity at very low body fat
CardarinePPAR-δ agonistFat-for-fuel switchEndurance, glycogen sparing, ↑HDL/↓trig
Yohimbineα2 antagonistStubborn-fat lipolysis (fasted)Spot-reduction of lower-back/ab fat
T3Active thyroid hormone↑ metabolic rateAggressive cut fat loss (catabolic, cardiac strain)
MK-677Ghrelin agonist↑ GH/IGF-1Fullness/vascularity, deep sleep, joint cushion, appetite ↑
TadalafilPDE5 inhibitorVasodilationPumps, vascularity, set-to-set endurance
Melanotan-2Melanocortin agonistPigmentationTan, appetite ↓, erection quality
SLU-PP-332ERR agonistExercise-mimetic signalling↑ fat oxidation/metabolic rate, no stimulant load
MOTS-cMitochondrial-derived peptideMetabolic flexibilityPrevents diet-induced insulin resistance
Methylene BlueMitochondrial electron cycler↑ ATP, waste clearanceOxidative-stress support in a hard cut (MAOI caution)
Metformin + SGLT2 + RetatrutideAMPK / renal glucose dump / GLP-1·GIP·GCGRInsulin-sensitivity restorationGlucose clearance + appetite suppression for the cut

The visual & performance drivers

Reading the drawer by goal rather than by drug:

Desired look / outputPrimary driversKey support
Fat loss / lean-outClenbuterol, ephedrine, T3Cardarine, yohimbine
Intracellular fullnessMK-677Tadalafil (blood volume)
Endurance & work capacityCardarineClenbuterol, tadalafil
Dryness, vascularity, sharpness(water management)Tadalafil (veins), clenbuterol
Insulin sensitivity / metabolic flexibilitySLU-PP-332, MOTS-c, glucose stackMethylene Blue, steps/cardio

And the indirect strength angle — none of these are anabolics, but three raise the weight on the bar through non-androgen routes:

  • MK-677 → intracellular hydration → joint/tendon cushion + better leverage on heavy compounds.
  • Tadalafil → pump-as-structural-support + faster recovery between sets → sustained power across a workout.
  • Cardarine → glycogen sparing → more reps at a high percentage of your max → more total volume → neurological strength adaptation over weeks.

Tiering the cut: light, medium, heavy

The single most important discipline with this drawer is not deploying the heavy artillery for a light job. You match the accelerator intensity to how lean you already are — the deployment pipeline escalating to meet the body-fat tier, never the reverse. Three tiers:

  • Tier 1 — light (you’re soft, or opening a mini-cut). Don’t go full-blast. Add ~10k steps a day, run a deficit or maintenance with protein held high, give a gentle thyroid nudge (T4 with a little T3), and clear glucose with the Metformin + SGLT2 (+ Retatrutide) combo, on top of your year-round Cardarine and injectable L-carnitine. A mini-cut here should be aggressive, brief (2–4 weeks), and hyper-efficient at restoring insulin sensitivity without crashing training.
  • Tier 2 — medium (a genuine mid-cut). Add the mitochondrial layer on top of Tier 1: SLU-PP-332 and MOTS-c for metabolic flexibility, and Methylene Blue for ATP and oxidative-waste clearance.
  • Tier 3 — heavy (lean, chasing a final peak before bulking back). Earned only when you’ve lean-bulked ~20+ weeks without much fat and want to get truly shredded for a short window. Skip the glucose-management layer — you're already insulin-sensitive. Run the full fasted-morning fat-loss routine (yohimbine + caffeine + tyrosine + creatine + coleus forskohlii), the metabolic stack (Cardarine, L-carnitine, MOTS-c, SLU-PP-332, Methylene Blue), thyroid plus HGH, and a short, low-dose fasted clenbuterol run with electrolyte support.

The tier is set by your body fat, not your impatience

The tier you deploy is decided by how lean you are (Pipeline 2’s read), not by how badly you want to be shredded. Stepping straight to the heavy stack while soft just burns through your CNS and your insulin sensitivity for nothing — and the moment a marker the monitoring watches turns the wrong way, the tier steps back down.

How this maps back to the framework

  • It’s the margin on the margin. Anabolics (Part 3) build the tissue; this drawer mostly reveals or sharpens it. If your training, diet, and base cycle aren’t dialled, none of it matters — the 10 rule one more time.
  • It’s mostly cut-phase. Fat-burners, T3, melanotan, and diuretics are contest/cut tools; MK-677 and tadalafil span phases. Year-round use of the stimulant fat-burners is how people damage their hearts.
  • It’s tiered, and the tier is set by body fat. The deployment pipeline escalates these tools to match how lean you are (Pipeline 2), never the reverse — a light job gets light tools.
  • Protection still rules. Everything in 4.0–4.2 applies on top — clenbuterol and ephedrine push BP and heart rate, T3 and MK-677 move glucose and thyroid markers, so the monitoring gets more important here, not less.

Up next

That’s the whole pharmacological toolbox — anabolics, protection, and now the performance/aesthetic drawer. But there’s one thread running underneath nearly every compound here: water, and the minerals that move with it. Part 4.4 — Electrolyte Management is where those factors converge — sodium, potassium, magnesium, and the water retention that shows up everywhere from EQ to clenbuterol. Then Part 5 assembles all of it: first the four-pipeline operating system that runs the whole practice as concurrent control loops, then a single worked three-year example (a calendar, a stack, a monitoring schedule, and a shopping checklist), and finally the budget that keeps it sustainable.

Part 4.3 Takeaways

Key concepts to internalize

  • This drawer is performance & aesthetics, not protection or anabolism — and it’s the margin on the margin: mostly cut/contest tools on an already-built physique.
  • Read every compound by its indirect effects — that’s what actually predicts the physique/performance outcome.
  • Fat-burners earn their keep late in a cut (clenbuterol, ephedrine, T3), with cardarine for endurance/lipids and yohimbine for stubborn fat — all with real cardiovascular cost.
  • MK-677 and tadalafil span phases — fullness/sleep and pumps/vascularity respectively, and both quietly add strength through non-anabolic routes.
  • Contest diuretics are the deadliest line in the series — expert-and-coach-only, no DIY, categorically different from BP-management diuretics.
  • Protection and monitoring matter more here, not less — stimulants and thyroid move exactly the markers Part 2 and Part 4 watch.

Your Realm Task List

  1. Ask whether you even need this drawer. Most of it is cut/contest-only — if you’re not lean and not prepping, the honest answer is usually “not yet.”
  2. Map any compound to its indirect effects before running it — know the downstream reason you’re using it, not just the marketing.
  3. Keep stimulant fat-burners short and low (clenbuterol, ephedrine), with electrolyte/taurine support and BP/HR tracking.
  4. Treat T3 as a contest tool — track FT3/FT4, taper, never year-round.
  5. Leave contest diuretics alone unless you’re a supervised competitor.
  6. Layer protection underneath — the ancillary stack and monitoring run through any realm phase.

Disclaimer

This article is harm-reduction education, not medical advice or a protocol. The compounds discussed are prescription-only, research chemicals, or banned substances in most jurisdictions, including Malaysia, and several are acutely dangerous — clenbuterol and ephedrine carry serious cardiovascular risk, T3 is catabolic and cardiac-straining, and contest diuretics have killed people (hence no doses for them here). Reference doses are illustrative of harm-reduction practice, not instructions. Individual response varies; work with a qualified physician and rely on bloodwork and monitoring before using anything here.

Sources & references

Footnotes

  1. The metabolic/mitochondrial drawer — SLU-PP-332 as an ERR agonist that mimics endurance-exercise signalling, and MOTS-c as a mitochondrial-derived peptide enhancing metabolic flexibility and resisting diet-induced insulin resistance — is cutting-edge and research-tier, with limited human long-term data. Treated here as harm-reduction education, not endorsement. ↩

  2. The cut-phase glucose-management combination — metformin (AMPK activation → peripheral insulin sensitisation and reduced hepatic glucose output), an SGLT2 inhibitor (empagliflozin/ertugliflozin → renal glucose excretion), and retatrutide (GLP-1/GIP/glucagon triple agonist → appetite suppression and metabolic-rate elevation) — is detailed, with within-family selection and cadence, in Part 4.2. Several members double as year-round protective ancillaries. ↩

Graph View

Backlinks